Predictors of minimal disease activity at 5-year follow-up
| All patients (n=197, MDA: n=75) | Female patients (n=114, MDA: n=35) | Male patients (n=83, MDA: n=40) | ||||
|---|---|---|---|---|---|---|
| Predictor | Age-adjusted univariate | Age-adjusted multivariate | Age-adjusted univariate | Age-adjusted multivariate | Age-adjusted univariate | Age-adjusted multivariate |
| Male gender | 1.93 (1.04 to 3.58)* | 1.62 (0.79 to 3.31) | ||||
| DAS28 baseline (per stdz unit) | 0.68 (0.48 to 0.96)* | 0.85 (0.53 to 1.36) | 0.59 (0.34 to 1.03) | |||
| DAPSA baseline (per stdz unit) | 0.50 (0.29 to 0.75)* | 0.60 (0.34 to 1.04) | 0.35 (0.15 to 0.84)* | |||
| Polyarthritis at baseline | 0.44 (0.23 to 0.83)* | 0.32 (0.13 to 0.78)* | 0.77 (0.30 to 1.98) | |||
| Axial disease at baseline | 2.61 (0.99 to 6.86)† | 4.58 (0.79 to 26.74) | 1.71 (0.52 to 5.63) | |||
| Mono/oligoarticular disease at baseline | 1.59 (0.86 to 2.91) | 2.17 (0.92 to 5.14) | 0.95 (0.39 to 2.33) | |||
| SJC baseline | 0.91 (0.83 to 0.99)* | 0.89 (0.78 to 1.01) | 0.93 (0.83 to 1.04) | |||
| TJC baseline | 0.88 (0.82 to 0.96)* | 0.94 (0.87 to 1.02) | 0.89 (0.80 to 0.99)* | 0.96 (0.70 to 1.39) | 0.88 (0.78 to 0.96)* | 0.94 (0.84 to 1.06) |
| HAQ baseline (per stdz unit) | 0.48 (0.32 to 0.70)* | 0.58 (0.34 to 0.95)* | 0.51 (0.30 to 0.86)* | 0.43 (0.23 to 0.82)* | 0.50 (0.26 to 0.95)* | |
| Global VAS baseline (per stdz unit) | 0.51 (0.36 to 0.73)* | 0.62 (0.39 to 0.99)* | 0.41 (0.23 to 0.74)* | |||
| Pain VAS baseline (per stdz unit) | 0.54 (0.39 to 0.76)* | 0.73 (0.37 to 1.01) | 0.39 (0.22 to 0.70)* | 0.37 (0.19 to 0.72)* | ||
| Months of delay (per stdz unit | 0.92 (0.87 to 0.97)* | 0.89 (0.83 to 0.94)* | 0.90 (0.83 to 0.97)* | 0.88 (0.80 to 0.96)* | 0.93 (0.87 to 1.00)* | 0.92 (0.84 to 1.01) |
| NSAID after baseline | 0.83 (0.44 to 1.59) | 0.55 (0.23 to 1.3) | 1.37 (0.51 to 3.70) | |||
| DMARD ever | 0.87 (0.47 to 1.62) | 0.81 (0.35 to 1.89) | 0.89 (0.35 to 2.30) | |||
| MTX ever | 1.11 (0.61 to 2.02) | 1.12 (0.48 to 2.57) | 1.07 (0.44 to 2.62) | |||
| Biologic ever | 1.36 (0.47 to 3.95) | 2.22 (0.59 to 8.38) | 0.72 (0.11 to 4.60) | |||
| Age baseline (per 10 years) | 0.88 (0.71 to 1.08) | 0.90 (0.71 to 1.15) | 0.85 (0.64 to 1.12) | 0.99 (0.70 to 1.39) | 1.03 (0.74 to 1.40) | 0.80 (0.52 to 1.22) |
Values are OR (95% CI).
*Statistically significant, p<0.05.
†In crude analysis without age adjustment, axial disease was a significant predictor of MDA (OR 2.6, 95% CI 1.06 to 6.72).
DAPSA, Disease Activity Index for Psoriatic Arthritis; DAS28, Disease Activity Score including 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; MDA, minimal disease activity; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; stdz, standardised; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.